John F. Paolini - Apr 10, 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role: CHIEF MEDICAL OFFICER
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol: KNSA
Transactions as of: Apr 10, 2023
Transactions value $: -$7,861
Form type: 4
Date filed: 4/11/2023, 05:06 PM
Previous filing: Apr 3, 2023
Next filing: Jul 27, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Common Share	Options Exercise		+2.5K	+6.22%		42.6K	Apr 10, 2023	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	-$7.86K	-734	-1.72%	$10.71	41.9K	Apr 10, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	+2.5K	+50.02%	$0.00	7.49K	Apr 10, 2023	Class A Common Share	2.5K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.